
Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer buff.ly/3ptuso6

Online news site based in Copenhagen, Denmark, covering the life science industries in Scandinavia and the rest of the world.

Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer buff.ly/3ptuso6

Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs" buff.ly/3ohxGvu $LUN.co

Novo Nordisk wins big on strong US dollar buff.ly/32XfHlO $NOVO $NVO



Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition buff.ly/3nMSpXP $DRNA $NOVO $NVO

Nykode Therapeutics CEO after another million-dollar deal: We have no competitors buff.ly/3oPSRDW $REGN

Novo Nordisk Foundation's CEO warns antibiotic resistance will be world's second-biggest killer buff.ly/30Wcq5B #AMR

Grass allergy sufferers wanted for Lundbeck phase I antibody study buff.ly/30UL2Vp $LUN.co

Huge acquisition scores Novo Nordisk an FDA-ready treatment buff.ly/3DxxbCP $NVO $NOVO

Novo Nordisk acquires Dicerna for USD 3.3bn buff.ly/3kNlVuA $NVO $NOVO

Pharmacosmos sees big potential in million-dollar acquisition buff.ly/3kKX0Yo

Positive CHMP opinion paves way for Lundbeck's Vyepti in Europe buff.ly/3C3RrKA $LUN.co

European interest in Wegovy expected to match US demand, says EVP at Novo Nordisk buff.ly/3wGqb3V $NOVO $NVO

Novo Nordisk within touching distance of European obesity market as CHMP recommends approval buff.ly/3ooCq0Z $NVO $NOVO

Dropping two drug candidates puts Genmab in a better position, says CEO buff.ly/30eAXSt $GEN $GMAB